Efficacy and Tolerability of high dose SARS-COV-2 Antibody Cocktail (Casirivimab-Imdivimab) in post covid-19 infection with Hodgkin’s lymphoma: A case report

A case report of 59 years old gentleman admitted post covid-19 infection with Hodgkin’s lymphoma, we have given high dose SARS-COV-2 Antibody Cocktail Casirivimab–Imdivimab (REGN-COV-2). These investigational monoclonal antibodies approved in November 2020 by the Food and Drug Administration for emergency use in mild and moderate COVID-19. These two noncompeting human IgG1 monoclonal antibody target the receptor-binding domain of the spike protein of SARS-CoV-2, prevent its entry into human cells, and reduce viral load. The purpose of the case report is to review that low incidence of serious adverse events that occurred or worsened during the observation period and of infusion-related or hypersensitivity reactions was observed and observed all the important renal and hepatic lab parameter before and after administration of SARS-COV 2 antibody cocktail there is no dramatic abnormality seen in the patient on safety and tolerability in COVID-19 treatment using Casirivimab and Imdevimab for the immune compromised Hodgkin’s lymphoma patient. In the clinical trial, REGN-COV-2 decreased viral load, particularly in patients with a non-initiated immune response (serum antibody-negative) and with high viral load at baseline. Casirivimab and imdevimab seem to be effective and safe antiviral therapy for hospitalized patients with COVID-19.